ImmunityBio Shares Surge on Promising Lung Cancer Trial Data

A Novel Mechanism Driving Investor Enthusiasm

ImmunityBio’s stock experienced a significant boost, climbing more than 8%, following the presentation of compelling new data from its Phase 2 clinical trial, QUILT-3.055. The data, unveiled at the World Conference on Lung Cancer, demonstrated that the company’s drug candidate, ANKTIVA, provided substantial survival benefits for patients with advanced non-small cell lung cancer who had ceased responding to conventional immunotherapy treatments.

This development introduces a potential turning point for the biotech firm, which has seen its share price decline more than 60% from its annual peak. The positive results could signal a reversal of fortune, pulling the equity out of its downward trend.